Myositis is an autoimmune disease. More precisely, it belongs to a group of conditions called idiopathic inflammatory myopathies, where the immune system mistakenly attacks healthy muscle tissue, causing weakness and inflammation. The disease is rare, affecting roughly 2 in every 100,000 people per year, with an overall prevalence of about 27 per 100,000.
That said, myositis isn’t a single condition. It’s an umbrella term covering several distinct subtypes, each driven by different autoimmune mechanisms and each carrying its own set of autoantibodies. One subtype, inclusion body myositis, blurs the line between autoimmune and degenerative disease, which is part of why the “is it autoimmune?” question comes up so often.
The Main Subtypes of Myositis
Over the past four decades, the discovery of specific autoantibodies in myositis patients has reshaped how doctors classify the disease. Rather than lumping everything together as “muscle inflammation,” specialists now recognize distinct subtypes based on which antibodies are present, which muscles are affected, and whether organs beyond the muscles are involved.
The major subtypes are:
- Dermatomyositis (DM): Causes muscle weakness alongside distinctive skin rashes. It’s associated with several specific autoantibodies and is now understood to be a type of acquired interferonopathy, meaning the immune system overproduces inflammatory signaling proteins that damage muscle and skin. About 50% of cases are linked to identifiable autoantibodies, while the rest are seronegative.
- Anti-synthetase syndrome (ASyS): Involves muscle weakness along with joint inflammation, lung disease, and other features that overlap with connective tissue disorders. This category absorbed many cases that were previously labeled polymyositis.
- Immune-mediated necrotizing myopathy (IMNM): Primarily targets muscle tissue with severe, sometimes rapid destruction of muscle fibers. It’s associated with two specific antibodies and can be triggered by cholesterol-lowering medications in some patients.
- Inclusion body myositis (IBM): The most common inflammatory myopathy in people over 45. It typically starts with weakness in the fingers and knees, often asymmetrically, and progresses slowly over years.
A fifth category has emerged in recent years: myositis triggered by cancer immunotherapy drugs, particularly immune checkpoint inhibitors. As these treatments have become more widely used, cases of drug-induced myositis have increased.
Why Inclusion Body Myositis Is Different
Inclusion body myositis is the outlier in the myositis family. While it does involve immune cells invading muscle tissue (just like other forms), it also has a degenerative component. Muscle biopsies from IBM patients show abnormal protein clumps and tiny vacuoles inside muscle fibers, features that look more like a degenerative disease than a purely autoimmune one.
The strongest evidence that IBM isn’t simply autoimmune: it doesn’t respond to immunosuppressive treatment. Steroids, which are the foundation of therapy for other forms of myositis, do little for IBM. Some patients experience temporary stabilization, but the disease progresses regardless. Biopsies taken after immunosuppressive treatment show continued protein buildup and vacuole formation in muscle fibers, suggesting that the degenerative process keeps running even when inflammation is dialed down. This resistance to immune-targeted therapy has led many researchers to argue that inflammation may not be the primary driver of IBM, even though it’s clearly present.
How Autoantibodies Help Identify the Type
One of the hallmarks of autoimmune disease is the presence of autoantibodies, immune proteins that target the body’s own tissues. Myositis-specific autoantibodies are now central to diagnosis and can predict which complications a patient is likely to face.
For example, antibodies to a protein called Jo-1 are associated with interstitial lung disease in myositis patients and may predict better responsiveness to steroid treatment. Antibodies to TIF1-gamma, found in some dermatomyositis patients, signal a high risk of an underlying cancer. Each subtype tends to cluster with its own set of antibodies, which is why blood testing has become a key part of the diagnostic workup alongside muscle enzyme levels and, in some cases, muscle biopsy.
When muscle tissue is actively being damaged, a protein called creatine kinase (CK) leaks into the bloodstream. In a healthy person, CK levels typically range from 22 to 200 IU/L. In active inflammatory myopathy, especially in severe cases or immune-mediated necrotizing myopathy, CK can rise dramatically. The highest levels tend to occur in conditions where muscle fibers are actively dying rather than just inflamed.
What Treatment Looks Like
Because most forms of myositis are autoimmune, treatment focuses on calming the immune system. The first step is typically high-dose corticosteroids, continued for four to eight weeks until muscle enzyme levels return to normal. From there, the dose is gradually tapered over months to find the lowest amount that keeps the disease in check.
If steroids alone aren’t enough, or if side effects become a problem, doctors add a second immunosuppressive medication. Patients with more serious features like difficulty swallowing or voice changes are more likely to need these additional medications early on. For cases that resist standard treatment, intravenous immunoglobulin (a concentrated dose of antibodies from donor blood) can be used as a short-term bridge, and targeted biologic therapies are an option for truly refractory disease.
Response to treatment varies. In a long-term study of juvenile dermatomyositis patients, about 71% achieved a complete clinical response, meaning their symptoms resolved. However, only about 19% reached full clinical remission, where the disease was inactive without ongoing medication. For many people, myositis becomes a chronic condition that requires long-term immune-suppressing therapy to manage, with periodic flares and adjustments.
Beyond Muscle Weakness
Myositis can affect more than muscles. The autoimmune process in several subtypes targets other organs, which is part of what distinguishes myositis from a simple muscle problem. Interstitial lung disease, where inflammation scars the tissue between the air sacs in the lungs, is one of the most significant complications. It’s particularly common in anti-synthetase syndrome and in dermatomyositis associated with certain antibodies.
Dermatomyositis, in particular, carries an elevated cancer risk. The association is strong enough that guidelines recommend cancer screening in newly diagnosed adults, especially those with TIF1-gamma antibodies. Some cases of myositis are classified as cancer-associated myositis, a rare autoimmune condition directly linked to an underlying malignancy.
Swallowing difficulty is another common complication across subtypes, occurring when the muscles of the throat are involved. This can range from mild discomfort to a serious functional problem that affects nutrition and carries a risk of aspiration.